Acticor Biotech announced on Thursday that a Phase 2/3 clinical trial had failed to meet its endpoints in the treatment of stroke, resulting in a suspension of its share price.

The biopharmaceutical company said that analysis of the initial results showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death 90 days after stroke.

The trial also failed to meet its secondary endpoint, the proportion of patients returning to life without disability 90 days after stroke.

Yannick Pletan, Chief Operating Officer and Chief Medical Officer, described the results as "extremely disappointing" and in contradiction with the results of the previous phase 1b/2a study.

This phase 1b/2a trial, the data for which were published last January, did indeed confirm the safety profile of glenzocimab, showing a reduction in mortality and intracerebral hemorrhage.

The latest Phase 2/3 study included 438 patients, of whom 421 were treated, including 211 in the arm with glenzocimab in combination with the reference stroke treatment.

Acticor shares were downgraded following this information.

Copyright (c) 2024 CercleFinance.com. All rights reserved.